Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 35

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 35
---
 of Certain Transactions.” In addition, on the closing of this offering, we will adopt a code of ethics and conduct
that will require our employees, officers and directors to disclose any situation that reasonably would be expected to give rise to a
conflict of interest.

Our management team has limited experience managing a public company.

Most members of our management
team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly
complex laws pertaining to public companies in the United States. Our management team may not successfully or efficiently manage our transition
to being a public company subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws
and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention
from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely
affect our business, financial condition, results of operations and prospects.

Any resurgence of the COVID-19 pandemic could adversely affect our business, financial condition and results of operations.

Public
health epidemics or outbreaks could adversely impact our business. In late 2019, a novel strain of COVID-19, also known as coronavirus,
was reported in Wuhan, China. Initially the outbreak was largely concentrated in China, but it rapidly spread to countries across the
globe, including in Israel and the United States. Many countries around the world, including in Israel and the United States, implemented
significant governmental measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on
travel and the movement of people, and other material limitations on the conduct of business.

If
there is a resurgence of COVID-19 its spread may materially affect us economically. While the potential economic impact
brought by, and the duration of, any future resurgence of the COVID-19 pandemic may be difficult to assess or predict, it has already
caused, and could result in further, significant disruption of global financial markets, reducing our ability to access capital, which
could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other companies have been
highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our Ordinary
Shares or other securities and such sales may be on unfavorable terms. To the extent that future waves of COVID-19 disrupt normal business
operations, we may face operational challenges with our services, and we likely will